Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » HemoGenix Launches Higher Throughput Version of Hemotox Test in Hopes of Spurring Sales to Pharma

HemoGenix Launches Higher Throughput Version of Hemotox Test in Hopes of Spurring Sales to Pharma

Jun 23, 2006
Premium

Stem-cell hemotoxicity testing firm HemoGenix this week announced the launch of a 384-well plate version of its flagship HALO bioluminescent assay system for determining the effects of drugs on hematopoietic stem cells.

HemoGenix, which has traditionally garnered the majority of its revenues from contract hemotoxicity testing, hopes that the new higher throughput format will spur direct sales of its assay kits to pharmaceutical companies wishing to perform such testing in house, HemoGenix CEO Ivan Rich said this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

More to Mix and Match

A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.

National Academy of Sciences May Expel Members

According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.

Nucleic Acids Research Papers on DNA-Bound Proteins, Transcriptional Activation, More

In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.

Pause Recommended

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.